Ernexa therapeutics inc ERNA.US Value Analysis
ERNA Value Score
3
24
15
- AI analysis rates ERNA with a lower value score of 2.
- It is mainly due to unstable operating cash flow, along with potential higher debt.
- Over the past 3 months, ERNA has maintained an average value rating of 1.5, close to the rating of 1.9 over the past 3 years, indicating low growth opportunities for enterprise value.
- Compared to all stocks in the Health Care sector, ERNA has a medium value rating.
ERNA Value Reference Factors
The Value score is derived from various data and factor information, integrated through AI algorithms. The following factors are part of the evaluation used by AI value scores.
Update to 2025/03/20 (Weekly Update)
ERNA Financial Forecast
Unit : USD
Update to 2025/5/9 (Quarterly Update)
ERNA Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | -3.2 | 50% | -28% | 0 | -100% | - | - |
Update to 2025/5/11 (Quarterly Update)
ERNA Historical Value Score
You can use historical scores of 3 or above to observe potential performance and make investment decisions.
ERNA Value Strategy Backtest
The following backtest is based on specified rules since 2007. Price chart shows buy/sell time, cumulative returns, and backtesting statistics.
The Backtest Result of ERNA from 2007/01 till Now
- -98.17%
- Cumulative Return
- -19.70%
- Annual Return
- 46.57%
- Volatility
- -0.42
- Sharpe Ratio
Statistics data for entering at or above a Value score of 4 and exiting at or below a Value score of 2 from January, 2007 to May, 2025. (Total Trades: 4)
| ERNA | Sector | US Overall Market | |
|---|---|---|---|
| Wining Rate | 25% | 45% | 54% |
| Avg Return | -48.4% | 62.9% | 72.8% |
| Avg Profit | 34.2% | 197.1% | 165.9% |
| Avg Loss | -75.9% | -45.1% | -34.6% |
| Avg Risk-Reward Ratio | 45.1% | 437% | 479.2% |
Update to 2025/5/10 (Daily Update)